Clinical Trials Browser

Phase 1 × INDUSTRY × vocimagene amiretrorepvec × Clear all

NCT04089163 2020-03-30

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Phase 1 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04327011 2020-03-30

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Phase 1 Terminated

65 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT02576665 2020-02-07

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Phase 1 Terminated

21 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Head and Neck Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01470794 2018-05-21

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Phase 1 Completed

58 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT01985256 2018-05-21

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Phase 1 Completed

17 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma